Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Sami A. Znati"'
Autor:
Mairead Daly, Ricky A. Sharma, Paul E Wilde, Henry F. J. Tregidgo, Matthew J Clarkson, Sarah Cooper, Z. A. Bascal, Helen Grimes, Sami A. Znati, Andrew L. Lewis, Julian Hague, S. Moinuddin, Steven Bandula, Christopher Stacey, Laura Beaton
Publikováno v:
The British journal of radiology. 95(1130)
Objective: To determine the feasibility of using radiopaque (RO) beads as direct tumour surrogates for image-guided radiotherapy (IGRT) in patients with liver tumours after transarterial chemoembolisation (TACE). Methods: A novel vandetanib-eluting R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7456149faf9807b84aec8ab4d7436b58
https://pubmed.ncbi.nlm.nih.gov/34762499
https://pubmed.ncbi.nlm.nih.gov/34762499
Autor:
Laura Beaton, Henry F.J. Tregidgo, Sami A. Znati, Sharon Forsyth, Nicholas Counsell, Matthew J. Clarkson, Steven Bandula, Manil Chouhan, Helen L. Lowe, May Zaw Thin, Julian Hague, Dinesh Sharma, Joerg-Matthias Pollok, Brian R. Davidson, Jowad Raja, Graham Munneke, Daniel J. Stuckey, Zainab A. Bascal, Paul E. Wilde, Sarah Cooper, Samantha Ryan, Peter Czuczman, Eveline Boucher, John A. Hartley, David Atkinson, Andrew L. Lewis, Marnix Jansen, Tim Meyer, Ricky A. Sharma
Publikováno v:
Journal of vascular and interventional radiology : JVIR. 33(9)
To assess the safety and tolerability of a vandetanib-eluting radiopaque embolic (BTG-002814) for transarterial chemoembolization (TACE) in patients with resectable liver malignancies.The VEROnA clinical trial was a first-in-human, phase 0, single-ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b33332a99f4fa341c5777365d9389f0
https://pubmed.ncbi.nlm.nih.gov/35526675
https://pubmed.ncbi.nlm.nih.gov/35526675
Autor:
Alice E. Hagan, Gary Phillips, Andrew L. Lewis, Adam Westhorpe, Andrew W. Lloyd, Sami A. Znati, Ricky A. Sharma, Rebecca Carter, Wendy M. Macfarlane
Publikováno v:
Anti-cancer drugs. 32(9)
Vandetanib-eluting radiopaque beads (VERB) have been developed for use in transarterial chemoembolization of liver tumours, with the goal of combining embolization with local delivery of antiangiogenic therapy. The objective of this study was to inve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dd228ce4e9f463f73a0456bdfe8ef0e
https://pubmed.ncbi.nlm.nih.gov/33929994
https://pubmed.ncbi.nlm.nih.gov/33929994
Autor:
Ricky A. Sharma, Graham Munneke, Tim Meyer, Samantha Ryan, Joerg-Matthias Pollok, Matthew J. Clarkson, Sarah Cooper, Jowad Raja, Julian Hague, Laura Beaton, Sami A. Znati, Helen Lowe, Dinesh K. Sharma, Paul E Wilde, Henry F. J. Tregidgo, Z. A. Bascal, John A. Hartley, Peter Czuczman, Eveline Boucher, Brian R. Davidson, Marnix Jansen, Sharon Forsyth, Steven Bandula, May Zaw Thin, Manil D Chouhan, Daniel J. Stuckey, Andrew L. Lewis
Publikováno v:
JMIR Research Protocols
Background Transarterial chemoembolization (TACE) is the current standard of care for patients with intermediate-stage hepatocellular carcinoma (HCC) and is also a treatment option for patients with liver metastases from colorectal cancer. However, T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5385589a8b29c22d06c6043e8ab89c76
http://europepmc.org/articles/PMC6777276
http://europepmc.org/articles/PMC6777276
Autor:
Laura Beaton, Henry F J Tregidgo, Sami A Znati, Sharon Forsyth, Matthew J Clarkson, Steven Bandula, Manil Chouhan, Helen L Lowe, May Zaw Thin, Julian Hague, Dinesh Sharma, Joerg-Matthias Pollok, Brian R Davidson, Jowad Raja, Graham Munneke, Daniel J Stuckey, Zainab A Bascal, Paul E Wilde, Sarah Cooper, Samantha Ryan, Peter Czuczman, Eveline Boucher, John A Hartley, Andrew L Lewis, Marnix Jansen, Tim Meyer, Ricky A Sharma
BACKGROUND Transarterial chemoembolization (TACE) is the current standard of care for patients with intermediate-stage hepatocellular carcinoma (HCC) and is also a treatment option for patients with liver metastases from colorectal cancer. However, T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::207b42a1cd162a61f956d9f90b2f245c
https://doi.org/10.2196/preprints.13696
https://doi.org/10.2196/preprints.13696
Autor:
Z. A. Bascal, Hassan Shahbakhti, Sami A. Znati, Adam Westhorpe, Jessica Prince, Petra Vlckova, Marcos Duran Vasquez, Chiara De Vellis, Marilena Loizidou, Rebecca Carter, Ricky A. Sharma
Publikováno v:
Cancers
Volume 12
Issue 7
Cancers, Vol 12, Iss 1878, p 1878 (2020)
Volume 12
Issue 7
Cancers, Vol 12, Iss 1878, p 1878 (2020)
Hepatocellular Carcinoma (HCC) is increasing in incidence worldwide and requires new approaches to therapy. The combination of anti-angiogenic drug therapy and radiotherapy is one promising new approach. The anti-angiogenic drug vandetanib is a tyros
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a47c5208361228e40437e84f095a30e
https://doi.org/10.3390/cancers12071878
https://doi.org/10.3390/cancers12071878